-
The Future Of Nano Technology
Categories
- Ai
- Alan Watts
- Anatomy
- Andropause
- Anti-Aging Medicine
- Arthritis
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ataxia
- Autism
- Biochemistry
- BioEngineering
- Biotechnology
- Bitcoin
- Chemistry
- Cryonics
- Cryptocurrency
- David Sinclair
- Dementia
- Diet Science
- Diseases
- Eczema
- Elon Musk
- Futurism
- Gene Medicine
- Gene Therapy
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Healthy Lifestyle
- Healthy Living
- HGH Physicians
- Hormone Optimization
- Hormone Replacement Therapy
- Hormone Replacement Treatment
- Human Genetic Engineering
- Human Immortality
- Human Longevity
- Human Reproduction
- Hypogonadism
- Hypopituitarism
- Hypothyroidism
- Immortality
- Immortality Medicine
- Inflammation
- Injectable Growth Hormone
- Integrative Medicine
- Life Skills
- Longevity
- Longevity Medicine
- Low T
- Machine Learning
- Mars Colony
- Medical School
- Menopause
- multiple-sclerosis
- Nano Medicine
- Nanomedicine
- Nanotechnology
- Neurology
- Parkinson's disease
- Pharmacogenomics
- Protein Folding
- Psoriasis
- Quantum Computing
- Regenerative Medicine
- Resveratrol
- Sermorelin Physicians
- Singularity
- Spacex
- Stem Cell Therapy
- Stem Cells
- Stemcell Therapy
- Testosterone
- Testosterone Physicians
- Transhuman
- Transhumanism
- Transhumanist
- Uncategorized
- Veganism
- Vegetarianism
- Vitamin Research
- Wellness
-
Recent Posts
- Cheap longevity drug? Researchers aim to test if metformin can slow down aging : Shots – Health News – NPR
- The U.S. Needs to ‘Get It Right’ on AI – TIME
- Big Tech keeps spending billions on AI. There’s no end in sight. – The Washington Post
- Racist AI Deepfake of Baltimore Principal Leads to Arrest – The New York Times
- A Baltimore-area teacher is accused of using AI to make his boss appear racist – NPR
Archives
Popular Key Word Searches
- centraltph
- bicarbonate and growth immunity ray peat
- vrcc neurology
- bibliotecapleyades/amrita-longevity-immortality
- cbr xmen anatomy
- Medical genetics wikipedia
- immortality medicine
- GrabPay
- Grab Pay Philippines
- GrabPay Vietnam
- GrabPay Philippines
- dr weil psoriasis
- what does recovered mean covid-19
- tony pantalleresco
- tony pantalleresco herbalist book
- herbsplusbeadworks
- herbsplusbeadworks website
- hailie vanderven
- princeton longevity center scam
- aetna genetic testing policy
- anatomy of hell
- biggie
- longevity claims
- augmentinforce tony pantalleresco
- tony pantalleresco website
| Search Immortality Topics: |
Category Archives: Global News Feed
AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) announced today that it completed its acquisition of GEDi Cube Intl Ltd. (“GEDiCube”). Renovaro, which means renew, combines the power of the AI Health Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech platform of Renovaro Biosciences to accelerate precision, personalized medicine, and a new era in healthcare innovation. The two subsidiaries will be under the parent organization, which was renamed Renovaro Inc.
Posted in Global News Feed
Comments Off on AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy…
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
See the article here:
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy...
Posted in Global News Feed
Comments Off on Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy…
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Originally posted here:
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Posted in Global News Feed
Comments Off on Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced the closing of its initial public offering of 1,000,000 shares of common stock at a public offering price of $7.00 per share. The gross proceeds to Telomir from the initial public offering were $7 million, before deducting underwriting discounts and commissions and other offering expenses. All the shares of common stock were offered by Telomir. The shares began trading on The Nasdaq Capital Market on February 9, 2024, under the ticker symbol "TELO."
Go here to read the rest:
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
Posted in Global News Feed
Comments Off on Telomir Pharmaceuticals Announces Closing of Initial Public Offering
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation…
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration
Posted in Global News Feed
Comments Off on Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation…
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2023 on Tuesday, February 27, 2024.
Read the rest here:
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
Posted in Global News Feed
Comments Off on Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024